428 related articles for article (PubMed ID: 31638645)
21. High Plasmatic Levels of Advanced Glycation End Products are Associated with Metabolic Alterations and Insulin Resistance in Preeclamptic Women.
García-Gómez E; Bobadilla-Bravo M; Díaz-Díaz E; Vázquez-Martínez ER; Nava-Salazar S; Torres-Ramos Y; García-Romero CS; Camacho-Arroyo I; Cerbón M
Curr Mol Med; 2020; 20(9):751-759. PubMed ID: 32077826
[TBL] [Abstract][Full Text] [Related]
22. AGEs accumulation with vascular complications, glycemic control and metabolic syndrome: A narrative review.
Pal R; Bhadada SK
Bone; 2023 Nov; 176():116884. PubMed ID: 37598920
[TBL] [Abstract][Full Text] [Related]
23. Association between Advanced Glycation End Products, Soluble RAGE Receptor, and Endothelium Dysfunction, Evaluated by Circulating Endothelial Cells and Endothelial Progenitor Cells in Patients with Mild and Resistant Hypertension.
Gryszczyńska B; Budzyń M; Begier-Krasińska B; Osińska A; Boruczkowski M; Kaczmarek M; Bukowska A; Iskra M; Kasprzak MP
Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31412635
[TBL] [Abstract][Full Text] [Related]
24. Impact of Advanced Glycation End products (AGEs) and its receptor (RAGE) on cancer metabolic signaling pathways and its progression.
Muthyalaiah YS; Jonnalagadda B; John CM; Arockiasamy S
Glycoconj J; 2021 Dec; 38(6):717-734. PubMed ID: 35064413
[TBL] [Abstract][Full Text] [Related]
25. Advanced glycation end product ligands for the receptor for advanced glycation end products: biochemical characterization and formation kinetics.
Valencia JV; Weldon SC; Quinn D; Kiers GH; DeGroot J; TeKoppele JM; Hughes TE
Anal Biochem; 2004 Jan; 324(1):68-78. PubMed ID: 14654047
[TBL] [Abstract][Full Text] [Related]
26. An update on the potential role of advanced glycation end products in glycolipid metabolism.
Wang X; Liu J; Yang Y; Zhang X
Life Sci; 2020 Mar; 245():117344. PubMed ID: 31981634
[TBL] [Abstract][Full Text] [Related]
27. The Potential Influence of Advanced Glycation End Products and (s)RAGE in Rheumatic Diseases.
Delrue C; Speeckaert R; Delanghe JR; Speeckaert MM
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769213
[TBL] [Abstract][Full Text] [Related]
28. Assay for advanced glycation end products generating intracellular oxidative stress through binding to its receptor.
Kobori T; Ganesh D; Kumano-Kuramochi M; Torigoe K; Machida S
Anal Biochem; 2020 Dec; 611():114018. PubMed ID: 33186591
[TBL] [Abstract][Full Text] [Related]
29. Advanced Glycation End Products (AGEs), Glutathione and Breast Cancer: Factors, Mechanism and Therapeutic Interventions.
Sharma AK; Sharma VR; Gupta GK; Ashraf GM; Kamal MA
Curr Drug Metab; 2019; 20(1):65-71. PubMed ID: 30207227
[TBL] [Abstract][Full Text] [Related]
30. Divergent Changes in Plasma AGEs and sRAGE Isoforms Following an Overnight Fast in T1DM.
Miranda ER; Fuller KNZ; Perkins RK; Beisswenger PJ; Farabi SS; Quinn L; Haus JM
Nutrients; 2019 Feb; 11(2):. PubMed ID: 30781793
[TBL] [Abstract][Full Text] [Related]
31. Advanced glycation end products (AGEs) and their involvement in liver disease.
Hyogo H; Yamagishi S
Curr Pharm Des; 2008; 14(10):969-72. PubMed ID: 18473847
[TBL] [Abstract][Full Text] [Related]
32. Action of metformin therapy against advanced glycation, oxidative stress and inflammation in type 2 diabetes patients: 3 months follow-up study.
Adeshara KA; Bangar NS; Doshi PR; Diwan A; Tupe RS
Diabetes Metab Syndr; 2020; 14(5):1449-1458. PubMed ID: 32769032
[TBL] [Abstract][Full Text] [Related]
33. Formation of Fructose-Mediated Advanced Glycation End Products and Their Roles in Metabolic and Inflammatory Diseases.
Gugliucci A
Adv Nutr; 2017 Jan; 8(1):54-62. PubMed ID: 28096127
[TBL] [Abstract][Full Text] [Related]
34. Role of advanced glycation end products (AGEs) and oxidative stress in diabetic retinopathy.
Yamagishi S; Ueda S; Matsui T; Nakamura K; Okuda S
Curr Pharm Des; 2008; 14(10):962-8. PubMed ID: 18473846
[TBL] [Abstract][Full Text] [Related]
35. Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes.
Tan KC; Shiu SW; Chow WS; Leng L; Bucala R; Betteridge DJ
Diabetologia; 2006 Nov; 49(11):2756-62. PubMed ID: 16969649
[TBL] [Abstract][Full Text] [Related]
36. Evidence that methylglyoxal and receptor for advanced glycation end products are implicated in bladder dysfunction of obese diabetic
Oliveira AL; Medeiros ML; Ghezzi AC; Dos Santos GA; Mello GC; Mónica FZ; Antunes E
Am J Physiol Renal Physiol; 2023 Oct; 325(4):F436-F447. PubMed ID: 37560771
[TBL] [Abstract][Full Text] [Related]
37. Advanced glycation end products as environmental risk factors for the development of type 1 diabetes.
Yap FY; Kantharidis P; Coughlan MT; Slattery R; Forbes JM
Curr Drug Targets; 2012 Apr; 13(4):526-40. PubMed ID: 22250649
[TBL] [Abstract][Full Text] [Related]
38. Advanced glycation end products and their adverse effects: The role of autophagy.
Sruthi CR; Raghu KG
J Biochem Mol Toxicol; 2021 Apr; 35(4):e22710. PubMed ID: 33506967
[TBL] [Abstract][Full Text] [Related]
39. Advanced Glycation End Products, Inflammation, and Chronic Metabolic Diseases: Links in a Chain?
Davis KE; Prasad C; Vijayagopal P; Juma S; Imrhan V
Crit Rev Food Sci Nutr; 2016; 56(6):989-98. PubMed ID: 25259686
[TBL] [Abstract][Full Text] [Related]
40. Advanced Glycation End Products in the Pathogenesis of Psoriasis.
Papagrigoraki A; Maurelli M; Del Giglio M; Gisondi P; Girolomoni G
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29156622
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
